joyjac
★    

Philippines,
2007-03-23 09:47
(7037 d 08:44 ago)

Posting: # 597
Views: 4,757
 

 Fixed Dose Combination Products [Design Issues]

Post reply
Dear colleagues,

Is it possible to apply scaled ABE on one active drug ingredient identified as a highly variable drug/drug product based on a previous study and on published literature, but make use of the conventional ABE approach for the other active drug component identified as not highly variable? Of course this will be stated a priori in the protocol. Your insight on this would be appreciated. Thanks.
 
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2007-03-23 12:27
(7037 d 06:04 ago)

@ joyjac
Posting: # 598
Views: 3,887
 

 Fixed Dose Combination Products

Post reply
Dear Joy,

IMHO there should be no problem with such an approach.
BTW, although I've never seen such a study, I think it's a great idea.
You are really creative!

If you want to perform your study for an application with the FDA, please note:
  1. There is not guideline on HVDs/HVDPs,
  2. FDA may want to see a minimum sample size (24 or 36?), and
  3. I would suggest waiting for results of the next meeting of the ACPSCP on 02 May 2007.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
385 visitors (0 registered, 385 guests [including 20 identified bots]).
Forum time: 19:31 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5